(Glu2)-TRH
Based on 1 Customer Validation
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.96%
- CAS No.: 85541-78-2
- 화학식: C15H22N4O6
- 분자량:354.36
-
보관:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-P0002
ProtirelinEndogenous Metabolite -
HY-12216
ResmetiromTHR-β Agonist -
HY-100856
PCO371PTHR1 Agonist -
HY-P2426
(D-Trp12,Tyr34)-pTH (7-34) amide (bovine)PTH Antagonist -
HY-126236
3,5-Diiodothyropropionic acidThyroid Hormone Analog -
HY-P1252
Parathyroid Hormone (1-34), bovinePTH Receptor Agonist -
HY-126236R
3,5-Diiodothyropropionic acid (Standard)Thyroid Hormone Analog -
HY-100856R
PCO371 (Standard)PTHR1 Agonist
All Endogenous Metabolite Isoforms
More
Biological Activity
제품 설명
In Vivo
(Glu2)-TRH (10 μmol/kg; IV) 10 min before Pentobarbital (60 mg/kg; i.p.) decreases the sleeping time by approximately 20% compared to the vehicle treated group[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Swiss-Webster mice (30 g)[1]
-
Dosage:1, 2, 5, 10, 15, 25, 50, 100 μmol/kg
-
Administration:IV; 10 min before Pentobarbital (60 mg/kg, i.p.)
-
Result:Dose-dependently attenuated TRH-induced (10 μmol/kg; iv) analeptic action.
Chemical Information
-
CAS No. 85541-78-2
-
Appearance Solid
-
분자량 354.36
-
화학식 C15H22N4O6
-
Color White to off-white
-
Sequence Shortening
Glp-EP-NH2
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
용액&용해도
In Vitro:
DMSO : 100 mg/mL (282.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
순도&문서
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8220 mL | 14.1099 mL | 28.2199 mL | 70.5497 mL |
| 5 mM | 0.5644 mL | 2.8220 mL | 5.6440 mL | 14.1099 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8220 mL | 7.0550 mL | |
| 15 mM | 0.1881 mL | 0.9407 mL | 1.8813 mL | 4.7033 mL | |
| 20 mM | 0.1411 mL | 0.7055 mL | 1.4110 mL | 3.5275 mL | |
| 25 mM | 0.1129 mL | 0.5644 mL | 1.1288 mL | 2.8220 mL | |
| 30 mM | 0.0941 mL | 0.4703 mL | 0.9407 mL | 2.3517 mL | |
| 40 mM | 0.0705 mL | 0.3527 mL | 0.7055 mL | 1.7637 mL | |
| 50 mM | 0.0564 mL | 0.2822 mL | 0.5644 mL | 1.4110 mL | |
| 60 mM | 0.0470 mL | 0.2352 mL | 0.4703 mL | 1.1758 mL | |
| 80 mM | 0.0353 mL | 0.1764 mL | 0.3527 mL | 0.8819 mL | |
| 100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.7055 mL |
(Glu2)-TRH Related Classifications
HY-P3960 Related Classifications
Powered by Bioz